AveXis (AVXS) Given a $110.00 Price Target by Canaccord Genuity Analysts
Several other research analysts have also recently weighed in on AVXS. Goldman Sachs Group reiterated a buy rating and set a $130.00 price objective on shares of AveXis in a research report on Friday, October 6th. UBS restated a buy rating and issued a $122.00 price target (up previously from $95.00) on shares of AveXis in a research report on Tuesday, October 3rd. Citigroup raised their price target on AveXis from $100.00 to $116.00 and gave the stock a buy rating in a research report on Monday, October 2nd. Jefferies Group raised their price target on AveXis to $118.00 and gave the stock a buy rating in a research report on Thursday, October 12th. Finally, Zacks Investment Research upgraded AveXis from a hold rating to a buy rating and set a $112.00 price target on the stock in a research report on Tuesday, October 24th. Four investment analysts have rated the stock with a sell rating, three have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock has an average rating of Hold and a consensus price target of $110.67.
Shares of AveXis (NASDAQ:AVXS) traded up $0.60 during trading on Thursday, reaching $98.94. The company’s stock had a trading volume of 436,800 shares, compared to its average volume of 426,246. AveXis has a fifty-two week low of $45.33 and a fifty-two week high of $108.27.
In related news, VP Sukumar Nagendran sold 1,780 shares of the company’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $97.25, for a total transaction of $173,105.00. Following the completion of the sale, the vice president now owns 1,780 shares in the company, valued at $173,105. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Brian K. Kaspar sold 15,000 shares of the company’s stock in a transaction on Monday, October 9th. The stock was sold at an average price of $101.46, for a total value of $1,521,900.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 52,340 shares of company stock worth $5,172,298. Insiders own 18.60% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its position in shares of AveXis by 41.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 24,871 shares of the company’s stock valued at $2,043,000 after buying an additional 7,321 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of AveXis by 31.8% during the 2nd quarter. Vanguard Group Inc. now owns 1,575,205 shares of the company’s stock valued at $129,419,000 after buying an additional 380,396 shares during the last quarter. Tocqueville Asset Management L.P. purchased a new position in shares of AveXis during the 2nd quarter valued at $552,000. TimesSquare Capital Management LLC purchased a new stake in AveXis during the 2nd quarter worth about $6,162,000. Finally, BB Biotech AG lifted its holdings in AveXis by 21.0% during the 2nd quarter. BB Biotech AG now owns 402,800 shares of the company’s stock worth $33,094,000 after purchasing an additional 70,000 shares in the last quarter. 92.88% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: “AveXis (AVXS) Given a $110.00 Price Target by Canaccord Genuity Analysts” was first published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://www.watchlistnews.com/avexis-avxs-given-a-110-00-price-target-by-canaccord-genuity-analysts/1766462.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.